¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Nitro-Caps Time Dose Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • exposure dose
    Æø·Î¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • erythema dose
    È«¹Ý¼±·®
  • fatal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • fractional dose
    1. ºÐÇÒ¿ë·® 2. ºÐÇÒ¼±·®
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    ÀûºÐ¼±·®
  • lethal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
  • fractional dose
    ºÐÇÒ¿ë·®, ºÐÇÒ¼±·®
  • immunizing dose
    ¸é¿ª¿ë·®, ¸é¿ª·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • infective dose
    °¨¿°¿ë·®, °¨¿°·®
  • integral dose
    Àû»ê¹æ»ç¼±·®
  • lethal dose
    Ä¡»ç¿ë·®, Ä¡»ç·®, Ä¡»ç¼±·®
  • loading dose
    ºÎÇϿ뷮, ºÎÇÏ·®
  • maintenance dose
    À¯Áö¿ë·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • appearance time
    ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • arm to tongue time test
    ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • hardening time
    °æÈ­½Ã°£(¡­ãÁÊà).
  • inertia time
    Ÿ¼º½Ã°£(öçàõãÁÊà)
  • influx time
    À¯ÀԽð£(êüìýãÁÊà).
  • inspiratory pause time
    Èí±âÈÄÈÞÁö½Ã°£.
  • inspiratory phase time
    Èí±â»ó½Ã°£.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • oral diagnostics
    ±¸°­Áø´ÜÇÐ(Ϣ˷òàÓ¨ùÊ).
  • oral diaphragm
    ±¸ÀúȾ°Ý¸·(Ï¢î¼üô̰د).
  • oral disease
    ±¸°­Áúȯ(Ϣ˷òðü´).
  • oral disinsertion
    °Å»ó¿¬Çظ®
  • oral dysodia
    ÀÔ¾ÇÃëÁõ
  • oral dysodia ³ª d. oris
    ÀÔ¾ÇÃëÁõ.
  • oral ecology
    ±¸°­»ýÅÂÇÐ
  • oral epithelium of free gingiva
    ¿Ü¿¬»óÇÇ(èâ æÞß¾ù«).
  • oral eroticism
    ±¸¾Ö¼º »öÁ¤(Ï¢äñàõßäï×), ±¸ °­±â»öÁ¤.
  • oral erotism
    ±¸°­±â¼º¾Ö, ±¸¾Ö¼º »öÁ¤.
  • oral fissure
    ±¸¿­
  • oral fissure ³ª rima oris
    ÀÔ¼úÆ´»õ, ±¸¿­ (Ï¢æñ).
  • oral fixation
    ±¸°­±â °íÂø(ͳó·)
  • oral floor
    ±¸°­Àú
  • oral floor
    ±¸°­Àú(Ϣ˷î¼).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • time interval
    ½Ã°£°£°Ý
  • time motion curve
    ½Ã°£¿îµ¿°î¼±
  • time of flight [=TOF]
    È帧½Ã°£, À¯Ã¼¼Óµµ°­Á¶
  • time of flight MR angiography
    À¯Ã¼¼Óµµ°­Á¶ ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • time of flight phenomenon
    À¯Ã¼¼Óµµ°­Á¶Çö»ó
  • time sharing
    ½Ã°£°øÀ¯, ½ÃºÐÇÒ
  • time velocity integral
    ½Ã°£¼ÓµµÁ¤¼ö
  • TM scan(Time motion)
    ½Ã°£¿îµ¿¹æ½Ä
  • TOF [=time of flight]
    È帧½Ã°£, TOF, À¯Ã¼ ¼Óµµ °­Á¶
  • transit time
    ÀüÀ̽ð£
  • transverse relaxation time
    ȾÃàÀ̿Ͻð£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
OTD oculotrichodysplasia; oral temperature device; organ tolerance dose
AD accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade...
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
DED date of expected delivery; defined exposure dose; delayed erythema dose
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
OC Oral contraception
OC Oral contraceptive
OCP Oral contraceptive pill
OCS Oral contraceptive steroids
OCA Oral contraceptives agents
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • equivalent dose
    µî°¡ ¼±·®
  • equivalent uniform dose
    µî°¡ ±ÕÁú ¼±·®
  • erythema dose
    Èï¹Ý ¼±·®
  • exposure dose
    Á¶»ç·®
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • immunizing dose
    ¸é¿ª·®
  • intoxicating dose
    Áßµ¶·®, Áßµ¶ ¼±·®
  • least fatal dose
    ÃÖ¼Ò Ä¡»ç·®
    ¾àÁ¦ÀÇ ¿ë·®À» °áÁ¤ÇÏ´Â ½ÇÇè¿¡¼­ 100¸í Áß 1¸íÀÌ¶óµµ »ç¸ÁÇÏ´Â ¹Ù·Î Á÷ÀüÀÇ ¿ë·®.
  • loading dose
    ºÎÇÏ ¿ë·®, ºÎÇÏ·®
  • maintenance dose
    À¯Áö·®, À¯Áö ¿ë·®
    ÀÏÁ¤ÇÑ »óŸ¦ À¯ÁöÇϱâ À§Çؼ­ ÇÊ¿äÇÑ ¾àÁ¦ÀÇ Åõ¿©·®.
  • maximal dose
    ÃÖ´ë ¿ë·®
  • maximum accumulation dose
    ÃÖ´ë ÃàÀû·®
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • mean effective dose
    50% À¯È¿·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
Simplified Oral Hygiene Index An index that measures the current oral hygiene status based upon the amount of debris and calculus occurring on six representative tooth surfaces in the mouth; often used in field surveys of periodontal disease.
(05 Mar 2000)
naso-oral Relating to the nose and mouth.
(05 Mar 2000)
surgery, oral A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region.
(12 Dec 1998)
diagnosis, oral Examination of the mouth and teeth toward the identification and diagnosis of intraoral disease or manifestation of non-oral conditions.
(12 Dec 1998)
oral <anatomy> Pertaining to the mouth, taken through or applied in the mouth, as an oral medication or an oral thermometer.
(18 Nov 1997)
oral biology That aspect of biology devoted to the study of biological phenomena associated with the oral cavity in health and disease (e.g., dental caries, mastication, periodontal disease).
(05 Mar 2000)
oral cancer Cancer within the mouth. Please see MedicineNet site on ral cancer for more information.
(12 Dec 1998)
oral candidiasis <gastroenterology, microbiology, oncology> Infection with a fungus of the genus Candida.
It is usually a superficial infection of the moist cutaneous areas of the body and is generally caused by Candida albicans, it most commonly involves the skin (dermatocandidiasis), oral mucous membranes (oral candidiasis), respiratory tract (bronchocandidiasis) and vagina (vaginal candidiasis or thrush). Rarely there is a systemic infection or endocarditis.
Oral candidiasis: describes a fungal (yeast) infection of the oral cavity due to Candida. It is common in infants, diabetics or those on chemotherapy and is well recognised in patients with HIV infection and AIDS.
Oesophageal candidiasis: Infection of the oesophagus by the yeast-like fungus Candidal albicans. Usually occurs in the immunocompromised individual (AIDS or following chemotherapy). Oral candidiasis is a predisposing factor but oesophageal involvement can occur without evidence of infection in the oral cavity. Symptoms include difficulty swallowing, pain on swallowing and oral lesions. Diagnosis is made using endoscopy.
Treatment is with antifungal agents such as ketoconazole or fluconazole.
Synonym: moniliasis, candidosis, oidiomycosis, blastodendriosis.
(16 Dec 1997)
oral cavity The region consisting of the vestibulum oris, the narrow cleft between the lips and cheeks, and the teeth and gums, and the cavitas oris propria.
Synonym: cavitas oris, cavum oris, mouth.
(05 Mar 2000)
oral cavity proper The space between the dental arches, limited posteriorly by the isthmus of the fauces (palatoglossal arch).
Synonym: cavitas oris propria.
(05 Mar 2000)
oral cholecystogram <radiology> Dose: 6 x 0.5 gram tablets after evening meal, peak opacification in 14-19 hrs. (13-35% excreted in urine) patient selection: bilirubin less than 5mg% (unless secondary to haemolysis), contraindicated in serious liver disease, relative contraindications in peritonitis, postoperative ileus, acute pancreatitis nonvisualization of gallbladder, cholecytectomy, obstruction of cystic duct, chronic cholecystitis, anomolous position of gall bladder, extrabiliary causes, fasting state, failure to reach absorptive surface of bowel (e.g. Malabsorption), deficiency of bile salts (Crohn disease, surgical resection of TI, liver disease, cholestyramine therapy, abnormal communication between biliary and GI tract)
(12 Dec 1998)
oral contraceptive Any orally effective preparation designed to prevent conception.
(05 Mar 2000)
oral epithelial nevus An autosomal dominant condition of the oral cavity characterised by soft, white or opalescent, thickened and corrugated folds of mucous membrane; other mucosal sites are occasionally involved simultaneously.
Synonym: familial white folded dysplasia, oral epithelial nevus.
(05 Mar 2000)
oral (erosive) lichen planus Oral manifestations of lichen planus characterised by white striae (Wickham's striae) of the oral mucous membrane and sometimes associated with ulceration; patients may or may not exhibit a history of cutaneous lichen planus.
(05 Mar 2000)
oral fissure The mouth slit; the aperture of the mouth.
Synonym: oral fissure.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • mean solar time
    Æò±Õ žç½Ã;Æò±Õ½Ã
  • monkey time
    ¼­¸Ó ŸÀÓ
  • mountain time
    »êÁö Ç¥ÁؽÃ
  • needle time
    (¿µ)(¹æ¼Û)·¹ÄÚµå À½¾Ç½Ã°£
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • part time
    Á¤»ó(±Ù¹«)½Ã°£ÀÇ ÀϺÎ
  • post time
    ¿ìÆí ¹ß¼Û ½Ã°£;¿ìÆí Áý¹è ½Ã°£;·¹À̽º ÃâÀü ¿¹Á¤ ½Ã°£
  • prime time
    (¶óµð¿À,ÅÚ·¹ºñÀüÀÇ)°ñµç ¾Æ¿ö
  • pulse time modulation
    ÆÞ½º½Ã º¯Á¶
  • question time
    Áú¹® ½Ã°£
  • quick time
    ¼Óº¸;1½Ã°£ 4¸¶ÀÏ
  • ragged time
    (³ëÁ£±â µîÀÌ)°í¸£Áö ¾ÊÀ½
  • reaction time
    ¹ÝÀÀ ½Ã°£
  • real time
    ½Ç½Ã°£;Áï½Ã ÀÀ´ä(»ç»ó°ú ±× µ¥ÀÌÅÍ Ã³¸®°¡ °°Àº ¼Óµµ·Î 󸮵Ê);Áï½Ã;µ¿½Ã
  • real-time
    ½Ç½Ã°£ÀÇ;(±â·Ï.¹æ¼ÛµîÀÌ)Áï½ÃÀÇ;µ¿½ÃÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á